Beyond Next Ventures–Backed Biomoneta Gets US FDA OK for Air-Decontamination Device
Bengaluru, Dec 2: Biomoneta, a pioneering healthtech company building advanced air-decontamination technologies, today announced that its flagship product Avata Rx, powered by its proprietary ZeBox® microbicidal technology, has received approval from the United States Food and Drug Administration (US FDA), marking the first time an Indian company has achieved FDA clearance in the air-decontamination category.
(Janani Venkatrama, Santanu Dutta & Arnam Ghatak, co-founders of Biomoneta)
This milestone is not only a validation of India’s deep-tech innovation capabilities but also reinforces the global urgency for clinically validated solutions that combat airborne pathogens, one of the most persistent sources of healthcare-associated infections (HAIs).
The approval is a major endorsement of Biomoneta’s scientific breakthrough and an important inflection point for Beyond Next Ventures India (BNV India), Japan-based early-stage deep-science fund known for backing transformative research-driven startups. BNV’s investment philosophy centers on supporting technologies rooted in deep science, real-world utility, and global scalability, and Biomoneta’s FDA recognition exemplifies this thesis.
A Breakthrough for Global Infection Control
Airborne pathogens including drug-resistant bacteria, fungi, spores, and viruses continue to challenge healthcare systems worldwide. Patient movement, ventilation inefficiencies, and high human activity make clinical spaces such as ICUs, operating rooms, procedure rooms, and labs highly susceptible to contamination. Beyond hospitals, elder-care centers, clinical labs, and home-care environments for immunocompromised individuals require continuous, dependable air-decontamination solutions.
The US FDA’s approval of Avata Rx underscores the global need for technologies that continuously trap and destroy airborne microbes in real time, forming a critical layer of defense in modern infection-control strategies.
A Vast and Accelerating Global Market Opportunity
Biomoneta enters the global arena at a time when the clean-air and infection-prevention sector is undergoing rapid transformation, with a combined global TAM spanning Healthcare Facilities (US $15–20B), Consumer/Residential Air Purifiers (US $17–20B), Commercial & Industrial HVAC Clean-Air systems (US $50–60B), HVAC OEM clean-air modules (US $20–30B), and Transportation IAQ solutions (US $8–12B), and its FDA approval now positions the company to access regulated markets that require clinically validated air-decontamination technologies, unlocking significant global pathways for adoption.
Scientific Innovation: The ZeBox® Advantage
Avata Rx, powered by ZeBox®, delivers broad-spectrum microbicidal action that inactivates airborne bacteria (including multidrug-resistant strains), viruses, fungi, hardy spores, and even Mycobacterium tuberculosis, one of the most difficult airborne pathogens to eliminate and, having been independently validated across multiple testing environments, including a Department of Biotechnology–funded IISc study that demonstrated its ability to destroy over 10 million airborne SARS-CoV-2 viral particles within 5 minutes, it now stands as one of the most scientifically validated air-decontamination technologies globally.
Impact Across Healthcare and Biotech Environments
Biomoneta’s products are already deployed across ICUs, NICUs, operating theatres, procedure rooms, ambulances and critical-care transport, as well as tissue-culture labs, biomedical research facilities, pharmaceutical cleanrooms, and change rooms, where they have demonstrated real-world reductions in microbial load—strengthening patient safety, protecting healthcare workers, and preventing contamination-related losses in biomanufacturing environments.
Speaking on the occasion, Jay Krishnan, Partner-India, Beyond Next Ventures (BNV), said, “Biomoneta represents exactly the kind of deep-science innovation Beyond Next Ventures exists to back- Technologies built on rigorous research, validated in real-world environments, and capable of creating global impact. FDA approval is not just a regulatory milestone, it is a scientific endorsement that places Biomoneta on the world stage. We are proud to support a team turning frontier microbiology into solutions that protect lives and redefine what clean-air technology can achieve.”
Arindam Ghatak, Co-founder & CEO, Biomoneta, further added, “FDA approval for Avata Rx is a powerful validation of nearly a decade of scientific persistence, engineering rigor, and an unwavering belief that clean air should be a fundamental standard of care. This milestone accelerates our mission to bring proven, real-time microbial elimination to healthcare and biotech environments worldwide. We are grateful to partners like Beyond Next Ventures, whose conviction in deep-tech innovation has helped us bring this breakthrough to the global market.”
Biomoneta has been recognized through multiple grants from the Government of India and the Government of Karnataka, and by industry bodies including the Confederation of Indian Industry (CII), the Association of Biotechnology Led Enterprises (ABLE), the FICCI/PwC LevelNXT program, and the FICCI/Lockheed Martin/Tata Trusts IIGP 2.0 program as one of India’s leading innovation-driven startups.